Clinical response in advanced non-small cell lung cancer with high PD-L1 expression and MET exon 14 skipping mutation: a case analysis of overcoming immunotherapy resistance and literature review

1

The case study highlights a 79-year-old male with advanced NSCLC exhibiting high PD-L1 levels and a MET exon 14 skipping mutation.
2

Initial treatment with the PD-1 inhibitor Tislelizumab resulted in a progression-free survival of 7 months before disease progression.
3

Switching to the MET tyrosine kinase inhibitor Savolitinib led to significant tumor reduction, although treatment was halted due to liver injury.
4

Reintroducing Tislelizumab after Savolitinib demonstrated successful disease control, suggesting potential for overcoming immunotherapy resistance.
5

This case underscores the importance of personalized treatment strategies for NSCLC patients with concurrent high PD-L1 expression and MET mutations.

1